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obtained from Brazilian official price lists. Results: 95,688 hospitalizations were 
identified with total length of stay (LOS) of 336,939 days; deaths and mortality rates 
were 866 and 0.91 respectively.1 The model estimated costs for the inpatient period 
assuming one dressing change every 3 days for MEDIHONEY and AG, considering 
in both cases a similar size. Cost per dressing change was estimated as USD35.80 
and US31.85 for AG and MEDIHONEY, with mean healing time of 53 and 31 days, 
respectively.2 Overall treatment costs were USD4,020,805.30 and USD3,577,169.00 
according to the LOS and USD632.46 and USD329.12 according to MHT/patient for 
AG and MEDIHONEY, respectively. MEDIHONEY-related incremental costs were 
USD31,492,834 indicating a cost-saving proﬁle. Adopting MEDIHONEY as wound 
management protocol would save USD29,025,998 for the 2013/2014-cohort. Clinical 
benefits for use of MEDIHONEY CALCIUM ALGINATE over AG include decreased 
risk of hypersensitivity to compounds, MEDIHONEY treatment is appropriate 
throughout wound healing process and MEDIHONEY does not induce microbial 
resistance.3 ConClusions: MEDIHONEY dressing demonstrates cost-effectiveness 
when compared to AG dressings. These results reinforce the need for evidence-based 
decision making and rational resource allocation; in addition to further studies 
including clinical outcomes data.
PMD44
Cost effeCtiveness of saCral neurostiMulation for overaCtive 
blaDDer in MexiCo
Soto H.1, Sanchez K.2, Escobar Juárez Y.2, Constanzo A.2, Ceballos R.3
1Universidad Autonoma Metropolitana, México D.F., Mexico, 2HS Estudios Farmacoeconómicos, 
Mexico City, Mexico, 3Medtronic, Mexico, Mexico
objeCtives: The objective is to develop a full economic evaluation of the cost 
effectiveness of using sacral neurostimulation versus botulinum toxin type A and 
augmentation cystoplasty in the treatment of overactive bladder in Mexico, from 
the perspective of the public health sector. Methods: A systematic literature 
review was conducted to identify articles to extract data on safety and efficacy of: 
sacral neurostimulation, botulinum toxin type A, and augmentation cystoplasty. 
A cost-effectiveness analysis was performed using a Markov model with a time 
horizon of 1 to 5 years. The effectiveness was measured as continence years and 
quality-adjusted life year (QALY). Only direct medical costs were considered, such 
as: medicine, surgery, devices, adverse events, days of hospitalization and labora-
tory studies; an analysis of incremental cost-effectiveness ratio (ICER) and incre-
mental cost-utility (ICU) was performed. To test the model and demonstrate the 
robustness, a probabilistic sensitivity analysis was performed, using Monte Carlo 
simulations. Results: Sacral neurostimulation showed better efficacy with 3.65 
continence years and 3.27 QALY’s with a cost of $279,538.11- The ICER over botuli-
num toxin A was 69,917.92, less than one time the Mexican GDP per capita, for the 
botulinum toxin the cost was 191,143.86 with 2.39 continence years and 2.13 QALY´s; 
for augmentation cystoplasty the cost was $205,049.02 with 3.19 continence years 
and 2.85 QALY’s. The probabilistic sensitivity analysis demonstrated that sacral 
neurostimulation is a cost-effective alternative, despite the modification of all the 
model’s variables. ConClusions: Sacral neurostimulation is a very cost-effective 
alternative for patients in the the public health care system in Mexico, being ICU 
and ICER less than one time the Mexican GDP per capita.
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objeCtives: The severity of the effect in reducing the risk of sudden cardiac 
death has a significant positive impact on the forecast as a whole and significantly 
reduces overall mortality rate among different categories of cardiology patients. 
Meanwhile, it imposes a significant burden on the healthcare budget of the Republic 
of Kazakhstan. Due to the fact that the CD’s implantation is an expensive method 
of treatment, the authors conducted a review of existing studies on the cost-effec-
tiveness of the CD in the application of additional functions - MRI-compatible and 
home monitoring function. Methods: The literature review of the efficacy and 
safety «MRI-compatible CD with home monitoring» were conducted on the database 
of the Cochrane Library, a database of bibliographic review on the effectiveness of 
medical intervention (DARE), database reviews of health technology assessment 
(HTA), PubMED, CADTH, NICE, Clinical Trials and TripDatabase. Results: Search 
results revealed 522 publications, and from this number 3 studies were selected 
for the final analysis. The remaining works were excluded due to non-compliance 
to the PICOS’ criteria. According to the data from representatives Biotronik and 
Medtronic in Kazakhstan the CD’s cost without MRI-compatible, completed with 
electrodes in Kazakhstan ranges $18.000-19.000. ConClusions: Application in 
clinical practice, MRI-compatible CD with home monitoring has significant advan-
tages - the almost complete absence of the risk of adverse events, the possibility 
of more frequent MRI as one of the main methods of diagnosis and early detection 
of various pathological conditions, the avoidance of unnecessary visits to patients 
without necessary evidence, revealing significant changes in the health status of 
patients in the constant monitoring; has a relatively small increase in the cost of a 
complete set of MRI-compatible CD with home monitoring in comparing with the 
cost of a set of CD without this function, an average of 33%.
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objeCtives: Major depressive disorder (MDD) is a debilitating disease that signifi-
cantly decreases quality of life. Repetitive Transcranial Magnetic Stimulation (rTMS) 
therapy is a safe, non-invasive, physical treatment for major depressive disorder. 
We evaluated the cost-effectiveness of rTMS compared with third-line antidepres-
tiveness of 24-hours Holter and up to 30 days ELR, each with different diagnostic 
yield, compliance, and costs in patients with syncope in Colombia. Methods: An 
analytical decision tree model was constructed including diagnostic yield, patient 
compliance, mortality rate, QALYs, associated costs to diagnosis and not having 
a diagnosis. Third party payer perspective, five year horizon and 3.5% discount 
rate for utilities and costs were assumed. Patient pathways and model inputs were 
ascertained from doctor interviews and literature search. Average market prices of 
US$175 for 24-hours Holter and US$627 for ELR were used. Micro-costing for avoided 
emergency visits and hospitalizations was done via Colombian key opinion leader 
interviews and official tariffs for costs of not having a diagnosis along five years. 
Uncertainty adjustments were done when judged appropriate. Incremental Cost 
Effectiveness ratio (ICER) was done, incorporating deterministic and probabilistic 
sensitivity analyses. Results: 24-Holter strategy had 19% diagnosis yield compared 
to 63% for ELR. Over a five year horizon, ELR strategy obtained more QALYs than 
24-Holter (2.62 vs. 2.18), at lower cost, been dominant over 24-hours Holter with 
US$2,165.6 incremental savings per incremental QALY. Sensitivity analysis showed 
the result to be particularly sensitive to disease and untreated syncope utilities 
and cost. The probabilistic sensitivity analysis showed a robust model with 95% 
confidence intervals of 1.83–2.57 QALYs for 24-hours Holter and 2.21–3.04 QALYs 
for ELR. ConClusions: Over a 5 year horizon, the ELR with greater utility (QALY) 
to lower costs, as demonstrated through greater incremental savings per QALY, was 
dominant over 24-Holter. The superior results of the ELR are attributable in part to 
the greater diagnostic yield and higher patient compliance.
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objeCtives: Drug-eluting stents (DESs) have been shown to reduce in-stent reste-
nosis and target vessel revascularization (TVR) in several large clinical trials. We 
conducted this study to explore the differences in the cost and clinical outcome 
of DESs and bare metal stents (BMSs). Methods: We retrospectively analyzed the 
clinical data and costs of patients with stable angina treated with coronary stents in 
2012 at a medical center in Taiwan. Results: We enrolled 245 patients treated with 
DESs and 194 patients treated with BMSs. The use of DESs is a lower rate of TVR com-
pared with that with BMSs (11% vs. 20%, p = 0.015). Compared with the DES group, 
the overall costs were significantly higher in the BMS group (NT$237727.0±89714.9 
vs. NT$187017.3±129713.5, p < 0.001). ConClusions: The use of DESs reduces the 
rate of TVR at 2 years after intervention, but is probably not cost-effective compared 
with BMSs in patient.
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objeCtives: To perform a full economic evaluation through a cost-effectiveness 
analysis of the use of paclitaxel-eluting balloon catheter (IN.PACT™ Admiral) in 
comparison with balloon catheter, for PTA in the treatment of peripheral obstruc-
tive artery diseases in Mexican population, from the perspective the public health 
care system in Mexico. Methods: The measure of effectiveness considered was 
decrease in the rate of target lesion revascularization (TLR). Information about effi-
cacy and safety of the intervention was obtained from a systematic review. Direct 
medical costs were considered (cost of devices as well as the procedure). An incre-
mental cost-effectiveness analysis was performed with a horizon of two years. To 
demonstrate the robustness of the model, univariate sensitivity analysis and proba-
bilistic sensitivity analysis were executed using Monte Carlo simulations. Results: 
Paclitaxel-eluting balloon catheter for PTA (IN.PACT™ Admiral) demonstrated good 
efficacy and safety producing a significant reduction in TLR at six months, which 
was maintained up to 24 months (estimated rate 14.4%), evaluated angiographi-
cally. This was significantly better than that obtained with conventional balloon 
angioplasty (estimated rate 40.3%) in the treatment of restenosis. Total average 
costs were $102,299.00 and $115,652.00 respectively. Therefore the incremental 
cost-effectiveness ratio (ICER) obtained showed that the paclitaxel-eluting balloon 
catheter for PTA (IN.PACT™ Admiral) is a dominant option. Clinical benefits were 
clearly demonstrated by the improvement in the ankle-arm index and Rutherford 
category. ConClusions: Paclitaxel-eluting balloon catheter for PTA (IN.PACT™ 
Admiral) proved to be more effective and less costly than the standard of care in 
the treatment of peripheral obstructive arterial disease, for Mexican public health 
care institutions.
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objeCtives: To develop cost-analysis of MEDIHONEY CALCIUM ALGINATE 
(MEDIHONEY) versus ACQUACEL AG (AG) dressings for chronic-wound treatment in 
adults, from perspective of Brazilian public payers. Methods: Data from Brazilian 
Hospital Information System from October 2013 to September 2014 was used to 
define the annual number of hospital admissions due to chronic wounds (only 
non-surgical records with L97.909 ICD-10 code included). The model assumed that 
patients are discharged at the time their wounds heal. No critically ill patients 
in ICUs were included. Only patients above 20 years old were included. Unit cost 
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conducted probabilistic sensitivity analysis. ConClusions: The cost-effectiveness 
of a lung cancer screening program varies widely and seems to largely depend on 
several key model parameters. Improved risk stratification might enhance the cost-
effectiveness of such a program.
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objeCtives: Evzio is a naloxone autoinjector indicated for lay overdose reversal in 
emergency treatment of known or suspected opioid overdose. The cost effectiveness 
of prescribing Evzio for “lay overdose reversal” was compared to “no lay reversal” 
using a health system perspective over one year. Methods: A decision analysis 
model was built using outcomes data obtained from randomized clinical trials and 
publicly available cost data. Adults at risk of heroin overdose in the US were included 
in the model. The primary outcome was Quality Adjusted Life Year (QALY). All data 
were subject to sensitivity analyses. Results: In the base case analysis, Evzio was 
found to cost health systems an extra $24,126 for every additional QALY saved due 
to overdose. Sensitivity analyses of variables found that the model was sensitive to 
the probability of emergency medical services being called if no Evzio was given, 
the probability of an overdose being witnessed, and the probability of survival if 
no medical treatment was given. ConClusions: The cost per QALY saved in pre-
scribing the naloxone autoinjector, Evzio, for patients at risk of opiate overdose is 
within acceptable cost effectiveness values for new therapies. When administered 
by friends, family members, and other witnesses of an opioid overdose, Evzio can 
be cost-effective.
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objeCtives: Atrial fibrillation (AF) is an arrhythmia that increases stroke risk. 
Left atrial appendage (LAA) occlusion with a LAA closure device is the first non-
pharmacologic strategy to undergo randomized, warfarin-controlled trials. It has 
demonstrated non-inferiority to the current standard, warfarin, for stroke and 
systemic embolism prevention. The objective of this study was to evaluate the 
cost-effectiveness of LAA closure relative to chronic warfarin therapy for stroke 
prevention in AF patients at elevated stroke risk. Methods: A Markov model was 
constructed from the payer perspective assuming a cohort of AF patients aged 65 
with a CHADS2 score≥ 2 at model entry. Clinical inputs were obtained from pub-
lished trials. Utilities were obtained from published studies assessing quality-of-
life in AF patients. Costs were obtained from published literature. Using quarterly 
cycles, the model was run over the patients’ remaining lifetime summing total costs 
and total quality-adjusted-life-years (QALYs) for each arm. Results: Total QALYs 
gained for the warfarin and device arms were 11.58 and 11.76, respectively. Total 
costs for the warfarin and device arms were $84,100 and $89,400, respectively. The 
base-case ICER for LAA closure compared to warfarin was $29,600/QALY. The model 
was most sensitive to underlying rates of stroke and intracranial hemorrhage (ICH) 
and the relative risk of stroke and ICH in the device arm compared to warfarin. It 
was relatively robust to costs and utilities. Monte Carlo simulation with 10,000 itera-
tions demonstrated LAA closure was cost-effective in 50% and 54% of simulations 
at thresholds of $50,000/QALY and $100,000/QALY. ConClusions: Though not yet 
available in the US, trial data suggests LAA closure is an option for anticoagulant-
eligible AF patients. It is estimated to be cost-effective at previously acceptable 
willingness-to-pay thresholds, but uncertainty around the ICER suggests a need 
for more precise parameter estimates. It remains a novel mechanism to improve 
outcomes in undertreated AF patients.
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objeCtives: Efforts to reduce the tuberculosis (TB) burden in many countries 
have recently focused on screening high-risk groups for latent TB infection (LTBI). 
Clinicians generally use the tuberculin skin test (TST) or interferon-gamma release 
assay (IGRA) to aid in LTBI diagnosis. We performed a systematic review of cost-
utility analyses in this area. Methods: Five electronic databases were used to iden-
tify studies. Study quality was assessed using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS). Population, setting, model type, perspec-
tive, costs, screening and treatment parameters, and incremental cost-effectiveness 
ratios (ICERs) were extracted. All costs were adjusted to 2013 US dollars, with ICERs 
< $20,000 considered highly cost-effective, ICERs between $20,000 and $100,000 
moderately cost-effective, and ICERs > $100,000 not cost-effective. Results: Of 
415 studies identified, 8 were included in the analysis, with 7 using Markov mod-
els and 1 using decision analysis. The decision to screen and how to screen for 
LTBI was evaluated in 5 studies, while the remaining three only evaluated how 
to screen. Perspectives used were societal (n= 4), healthcare program (n= 2), and 
healthcare system (n= 2). Studies evaluating immigrants found adult screening 
highly cost-effective with a TST (n= 1) and moderately cost-effective with an IGRA 
(n= 1). Screening of the foreign-born (n= 1) was moderately cost-effective with an 
IGRA until 44 years of age. Screening for HIV was found to be highly cost-effective 
with a TST (n= 3) and moderately cost-effective with an IGRA (n= 1). Screening in 
those with renal diseases (n= 2) and diabetes (n= 1) was found to be not cost-effec-
tive; screening in other immunocompromised populations was not cost-effective 
(n= 1). ConClusions: Screening of HIV patients with a TST is highly cost-effective 
and screening of immigrants and foreign-born with an IGRA is moderately cost-
sant medication for the treatment of adults with MDD who have failed at least two 
adequate courses of antidepressants. Methods: A three-year Markov microsimu-
lation model with two-month cycles was used to compare the costs and quality-
adjusted life years (QALYs) of rTMS and a mix of antidepressants (including selective 
serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, 
tricyclics, noradrenergic and specific serotonergic antidepressants and monoam-
ine oxidase inhibitors). The model synthesized data sourced from a meta-analysis, 
published literature, national cost reports and expert opinions. Incremental cost-
utility ratios were calculated and uncertainty of the results was assessed using 
univariate and probabilistic sensitivity analyses. Results: Compared with anti-
depressant medication therapy, rTMS is a dominant/cost-effective alternative for 
patients with treatment-resistant depressive disorder. The model predicted that 
QALYs gained with rTMS was higher than for antidepressant medications (1.25 ver-
sus 1.18 QALYs) while costs were slightly less (AUD 31,003 versus AUD 31,190). The 
treatment response rate, using the Hamilton Depression Rating Scale 17, was 16.8% 
for antidepressant medications and 37.5% for rTMS. In the Australian context at the 
willingness-to-pay threshold of AUD 50,000 per QALY gain, the probability that rTMS 
was cost-effective was 73%. Sensitivity analyses confirmed the model stability and 
superiority of rTMS compared with antidepressant medications. ConClusions: 
While both antidepressant medications and rTMS are clinically effective treatments 
for MDD, rTMS is shown to outperform antidepressants in terms of cost-utility 
for patients who have failed at least two adequate courses of pharmacotherapies. 
The study shows that rTMS is a cost-effective therapy alterative for patients with 
treatment-resistant depression without the many side-effects of pharmacotherapy.
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objeCtives: Patients with non-ST elevation myocardial infarction are managed 
based visual assessment of coronary angiography, which can be inaccurate and 
subjective. A randomized pilot trial has investigated an alternative approach using 
physiology-guided management with fractional flow reserve that may optimize 
outcomes. Objective was to estimate the cost-effectiveness of FFR-guided manage-
ment vs. coronary angiography. Methods: A trial-based economic evaluation was 
conducted (n= 350). We adopted a UK National Health Service perspective. Part I of 
the analysis used raw, unadjusted costs and QALYs assembled using individual 
resource use and EQ5D responses from the RCT. Part II used statistical modelling 
to model the effect pathway of FFR by conditioning total costs and QALYs on the 
treatment decision (coronary artery bypass graft (CABG), medical therapy and per-
cutaneous coronary intervention (PCI)). Results were then applied to treatment 
decision distributions following FFR or standard care management. Uncertainty in 
GLM coefficients, unit cost parameters and sampling were incorporated using boot-
strapping and Monte Carlo methods. Results: FFR reduced revascularization by PCI 
or CABG (OR 0.52; 95%CI: 0.28 – 0.94; p= 0.022). Part I: FFR led to a mean cost savings 
(£8,253 vs. £8,603; difference: –£305 [SD= £519]). Likely drivers of cost savings were 
length of stay (-£331 [£342]) and index year health events (-£217 [£223]). However, 
low information size contributed to their large imprecision. Incremental QALYs 
were comparable (0.811 vs. 0.799; diff: 0.013 [0.023]). Part II: FFR led again to a mean 
cost savings (£8,328 vs. £8,532; difference: –£204 [£305]) and comparable incremen-
tal QALYs (0.801 vs. 0.806; diff: –0.005 [0.004]). The probability of cost-effectiveness 
remained comparable over common willingness-to-pay (70-75%). ConClusions: 
Early evidence suggests FFR may be cost saving and comparable in QALYs. However, 
considerable uncertainty persists. We also prescribe specific design considerations 
for a future trial, including information size suggestions, follow-up frequency and 
outcomes to aid modelling/lifetime extrapolation.
PMD48
Cost-effeCtiveness analyses of lung CanCer sCreening strategies 
using low Dose CoMPuteD toMograPhy â€ “ a systeMatiC review
Raymakers A.J.1, Whitehurst D.G.2, FtizGerald J.M.1, Lam S.3, Mayo J.1, Lynd L.1
1University of British Columbia, Vancouver, BC, Canada, 2Simon Fraser University, Burnaby, BC, 
Canada, 3BC Cancer Agency, Vancouver, BC, Canada
objeCtives: Lung cancer is the leading cause of cancer related mortality in North 
America. This is attributable to it often being diagnosed at an advanced stage. Low 
dose computed tomography (LDCT) is a tool that can be used to potentially detect 
lung cancer at an earlier stage thereby improving patient outcomes. Recently, the 
National Lung Screening Trial (NLST) has shown that this method of screening 
can produce significant mortality reductions; however, whether such a program is 
cost-effective has not yet been well-established. Methods: We searched MEDLINE, 
EMBASE, EBM Reviews - Health Technology Assessment, the National Health Service 
(NHS) Economic Evaluation Database, and the Cochrane Database of Systematic 
Reviews. We included studies that presented a cost-effectiveness analysis of LDCT as 
a method of screening for lung cancer. Studies published prior to 2000 were excluded 
based on advances in imaging technologies. Costs are presented in 2012 United 
States dollars. Results: Thirteen studies were identified that met the criteria for 
inclusion. Ten studies were from the United States, and one each from Australia, 
Israel, and Japan. Most studies evaluated an annual screening program while four 
studies evaluated one time only screening. Incremental cost-effectiveness ratios 
(ICERs) were extracted for comparison and varied markedly between $8 186/LYG to 
$195 758/LYG (life year gained) or for quality-adjusted life years (QALYs): $1 494/QALY 
to $150 772/QALY. The model results seemed to be sensitive to several parameters 
including: the prevalence of lung cancer, the cost of LDCT screening, inclusion and 
characteristics of a smoking cessation program, the stage at which lung cancer was 
detected, and the lead-time associated with screening. Only one identified study 
